Prosecution Insights
Last updated: November 13, 2026
Application No. 17/282,774

Combination Therapy for Treating Cancer with an Intravenous Administration of a Recombinant MVA and an Immune Checkpoint Antagonist or Agonist

Non-Final OA §112
Filed
Apr 04, 2021
Priority
Oct 05, 2018 — EU 18199002.9 +2 more
Examiner
LU, CHENG
Art Unit
1642
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Bavarian Nordic A/S
OA Round
4 (Non-Final)
53%
Grant Probability
Moderate
4-5
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allowance Rate
119 granted / 223 resolved
-6.6% vs TC avg
Strong +65% interview lift
Without
With
+65.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
64 currently pending
Career history
297
Total Applications
across all art units

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION The amendment filed May 25, 2026 in response to the Office Action of December 23, 2025 is acknowledged and has been entered. Claims 20, 26, 27, 29, 33, and 34 have been amended. Claims 25 and 32 have been cancelled. Claims 20-22, 26-31, and 33-35 are pending and under consideration. In view of cancellation of claims 25 and 32, the 112(a) rejection set forth in the previous Office Action of December 23, 2025 is hereby withdrawn. As set forth in the previous Office Action of December 23, 2025, paragraph [0047] and FIG. 21 of the instant publication US 2024/0269254 A1 show increased overall survival and tumor reduction in IV administration of rMVA-CD40L (MVA-AH1A5-p15e-TRP2-CD40L) combined with anti-PD1 checkpoint blockade in C57BL/6 mice bearing MC38 colon cancer (also see Example 17). Prior art does not teach or suggest a recombinant MVA expressing the specific combination of TAAs (AH1A5, p15e and TRP2) and CD40L. Prior art does not teach or suggest administering the claimed recombinant MVA with an anti-PD-1 antibody for reducing tumor size and/or increasing survival in a subject with colon cancer. Information Disclosure Statement The Information Disclosure Statement filed on 05/25/2026 has been considered and entered by examiner. MAINTAINED?MODIFIED REJECTIONS Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 20-22, 26-31, and 33-35 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 20 recites both a product (a combination comprising (a) a recombinant modified Vaccinia Ankara (MVA) and (b) an anti-PD-1 antibody) and a process (wherein intravenous administration of (a) and administration of (b) to the cancer patient), which renders the claim indefinite. It is unclear whether the claimed “a combination therapy” is directed to the product (the claimed combination) or to the process (a method using the combination). While it is proper to have a product by process claim or recite intended used of the product, however, in this case, the claim recites steps of using the product. A product and process in the same claim is indefinite. See MPEP2173.05(p). Claims 21, 22, and 26-28 are also rejected because these claims depend on claim 20. Claim 29 is drawn to administering the combination therapy of claim 20 which renders the claim indefinite because it is unclear if the method just comprises administering MVA/PD-1 antibody combination of claim 20, or also performing the steps of claim 20 in addition to the steps of claim 29. Claims 30, 31, 33-35 are also rejected because these claims depend on claim 29. Response to Arguments For the 112(b) rejection, Applicant argues: Applicant respectfully disagrees with these conclusions in the Office Action, but nevertheless, in order to advance prosecution, claim 20 has been amended for clarification. Claim 20 now recites a combination therapy for reducing tumor size and/or increasing survival in a cancer patient, the combination comprising: (a) a recombinant modified Vaccinia Ankara (MVA) virus encoding tumor-associated antigens (TAAs) AH1A5, p15e, and TRP2 and further encoding CD40 Ligand (CD40L); and (b) an anti-PD-1 antibody; wherein intravenous administration of (a) and administration of (b) to the cancer patient reduces tumor size and/or increases the survival rate of the cancer patient as compared to a non-IV administration of (a) or an administration of (b) alone. Applicant’s arguments have been fully considered but they are not persuasive. Because the combination therapy of claim 20 still recites both a product (a combination comprising (a) a recombinant modified Vaccinia Ankara (MVA) and (b) an anti-PD-1 antibody) and a process (wherein intravenous administration of (a) and administration of (b) to the cancer patient). Accordingly, it is still unclear whether the method of claim 29 just comprises administering MVA/PD-1 antibody combination of claim 20, or also performing the steps of claim 20 in addition to the steps of claim 29. Thus, the 112(b) rejections are maintained for the reasons of record. Conclusion No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHENG LU whose telephone number is (571)272-0334. The examiner can normally be reached Monday-Friday 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at (571)270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHENG LU/Examiner, Art Unit 1642 /PETER J REDDIG/ Primary Examiner, Art Unit 1646
Read full office action

Prosecution Timeline

Show 3 earlier events
Dec 27, 2024
Response Filed
Mar 12, 2025
Final Rejection mailed — §112
Sep 12, 2025
Request for Continued Examination
Sep 18, 2025
Response after Non-Final Action
Dec 23, 2025
Non-Final Rejection mailed — §112
May 25, 2026
Response Filed
Aug 03, 2026
Final Rejection mailed — §112
Oct 20, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774471
ENGINEERED STREPTOMYCES ALBUS STRAINS
6y 0m to grant Granted Oct 27, 2026
Patent 12734202
ONCOLYTIC VIRUS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR FOR TREATING TUMORS
3y 10m to grant Granted Sep 15, 2026
Patent 12723080
MONOCLONAL ANTIBODY-CYTOKINE FUSION PROTEIN DIMER AND APPLICATION THEREOF
4y 8m to grant Granted Sep 01, 2026
Patent 12715921
ANTI-PD-1 ANTIBODIES FOR TREATMENT OF LUNG CANCER
2y 6m to grant Granted Aug 25, 2026
Patent 12692517
CRISPR/CAS12F ENZYME AND SYSTEM
5y 3m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
53%
Grant Probability
99%
With Interview (+65.0%)
High
PTA Risk
Based on 223 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month